Subglottic Extramedullary Plasmacytoma With Light Chain Multiple Myeloma Masquerading as Adult-Onset Asthma

Gan, Yijin Jereme; Chopra, Akhil; Kanagalingam, Jeevendra

doi:10.1016/j.jvoice.2013.10.016

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is usually treated locally with CO2 laser excision and systemic therapy for treating the underlying MM. Werner in 1991 reported 111 cases of laryngeal plasmacytoma of which 21 cases had underlying LCMM [ 11 ]. Wein in 2002 reviewed 12 cases of plasmacytoma of subglottis.…”

Section: Reviewmentioning

confidence: 99%

“…EMD mainly involves skin, nasopharynx, larynx, upper respiratory tract, and central nervous system (CNS). Overall, more than 90% of EMDs are diagnosed in the head and neck; however, EMD constitutes less than 1% of all head and neck malignancies [ 11 ]. The CNS involvement is estimated in 1% of patients and exhibits a poor prognosis with a median survival reported to be one to two months [ 12 - 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring

Rafae¹,

Malik²,

Zar³

et al. 2018

Cureus

View full text Add to dashboard Cite

Light chain multiple myeloma (LCMM) constitutes approximately 15% of patients with multiple myeloma (MM). It has a poorer prognosis when compared to immunoglobulin (Ig) G or IgA variant. We performed a comprehensive literature search on LCMM and identified a total of 390 articles. After a detailed screening, six studies involving a total of 1054 LCMM patients were included. A literature review revealed bone pain and renal failure as the most common initial sign and symptoms while extramedullary disease (EMD) was acquired later during the progression of the disease. Bortezomib has shown superior efficacy in LCMM patients over nonbortezomib regimens as demonstrated by better overall response rate (95.5% vs. 60%), progression-free survival (PFS) (25% vs. 9% at two years), and overall survival (OS) (24% vs. 9% at five years). Moreover, better PFS was seen, when bortezomib was used in combination with bendamustine compared to dexamethasone (95% vs. 25% at two years). Similarly, better OS (90% at two years) was observed with bortezomib in combination with bendamustine. Monitoring of disease should include serum free light chain levels, as literature review revealed that serum assays were more sensitive in indicating the disease and predicting PFS and OS as compared to urine assays. We provide presentation patterns, clinical rarities, management strategies including their efficacy, and disease monitoring in patients with LCMM in our review paper.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring

Rafae¹,

Malik²,

Zar³

et al. 2018

Cureus

View full text Add to dashboard Cite

show abstract

“…The patients mainly presented with unspecific symptoms, typical for all laryngeal tumours, i.e., dyspnoea, hoarseness, and cough ( Table 1 , Table 2 and Table 3 ). The symptoms reported in the literature additionally comprised dysphonia, dysphagia, stridor, sore throat, foreign body sensation in the throat, or intermittent wheezing, depending on the involved larynx structures [ 113 , 116 , 128 ]. Of note, none of the reported symptoms is pathognomonic for PCM of the larynx.…”

Section: Discussionmentioning

confidence: 99%

Solitary Extramedullary Plasmacytoma of the Larynx and Secondary Laryngeal Involvement in Plasma Cell Myeloma: Single-Centre Retrospective Analysis and Systematic Literature Review

Szczepanek

Drozd-Sokołowska

Sokołowski

et al. 2022

JCM

View full text Add to dashboard Cite

The involvement of the larynx in plasma cell myeloma (PCM) may manifest as solitary extramedullary plasmacytoma of the larynx (sEMP-L) or as infiltration of the larynx during newly diagnosed or relapsed systemic disease with bone marrow involvement (plasma cell myeloma with laryngeal involvement, PCM-L). To increase knowledge about these rare conditions, we performed a retrospective analysis along with a comprehensive literature review of cases of sEMP-L or PCM-L. Six patients (two sEMP-L and four PCM-L) were identified in our tertiary laryngological centre from 2009 to 2021, constituting 0.88% of all malignant laryngeal tumours. The literature search yielded 187 cases, including 152 sEMP-L and 35 sPCM-L. A comparison of baseline characteristics between sEMP-L and PCM-L performed in the combined cohort of cases from literature review and retrospective analysis revealed that patients with sEMP-L were younger (56 vs. 64 years, p ≤ 0.001) and presented less commonly with thyroid or cricoid cartilage involvement (2.2% vs. 30.8%, p ≤ 0.001). The prognosis of sEMP-L was better than PCM-L (overall survival 86% vs. 55% at 5 years, p = 0.002). Analysis of potential factors that could influence progression-free survival (PFS) in the group of sEMP-L revealed that male sex and cartilage involvement negatively affected PFS in univariate analyses, while only cartilage involvement retained statistical significance in multivariate analysis (HR = 19.94, p = 0.024). In conclusion, PCM with laryngeal involvement is sporadic. Secondary involvement of the larynx during PCM might be more common than sEMP-L and is associated with worse survival. The involvement of cartilage adversely influences the outcome of sEMP-L.

show abstract

Nonsquamous Pathologic Diseases of the Hypopharynx, Larynx, and Trachea

Palma¹,

Sandison²,

Zidar³

et al. 2021

Gnepp's Diagnostic Surgical Pathology of the Head and Neck

View full text Add to dashboard Cite

Subglottic Extramedullary Plasmacytoma With Light Chain Multiple Myeloma Masquerading as Adult-Onset Asthma

Cited by 4 publications

References 12 publications

An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring

An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring

Solitary Extramedullary Plasmacytoma of the Larynx and Secondary Laryngeal Involvement in Plasma Cell Myeloma: Single-Centre Retrospective Analysis and Systematic Literature Review

Nonsquamous Pathologic Diseases of the Hypopharynx, Larynx, and Trachea

Contact Info

Product

Resources

About